PainReform Starts Phase II Trial for OcuRing™-K
Ticker: PRFX · Form: 6-K · Filed: Dec 2, 2025 · CIK: 1801834
| Field | Detail |
|---|---|
| Company | Painreform Ltd. (PRFX) |
| Form Type | 6-K |
| Filed Date | Dec 2, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, drug-development, ocular-therapy
TL;DR
PainReform kicks off Phase II for OcuRing™-K drop-less eye therapy on Dec 2, 2025.
AI Summary
On December 2, 2025, PainReform Ltd. announced the commencement of its Phase II trial for OcuRing™-K, a drop-less sustained-release ocular therapy developed by LayerBio. This marks a significant step in the development of their innovative drug delivery system for eye conditions.
Why It Matters
The initiation of a Phase II trial is a critical milestone, indicating progress towards potential regulatory approval and commercialization of a new treatment option for ocular conditions.
Risk Assessment
Risk Level: medium — Clinical trial progression, especially to Phase II, carries inherent risks related to efficacy, safety, and regulatory hurdles.
Key Players & Entities
- PainReform Ltd. (company) — The company filing the report and initiating the trial.
- OcuRing™-K (product) — The name of the sustained-release ocular therapy undergoing development.
- LayerBio (company) — The developer of the OcuRing™-K therapy.
- December 2, 2025 (date) — The date of the press release announcing the trial commencement.
FAQ
What is the purpose of the OcuRing™-K Phase II trial?
The press release does not specify the exact purpose of the Phase II trial, but it is a step in the development of LayerBio's drop-less sustained-release ocular therapy.
Who developed OcuRing™-K?
OcuRing™-K was developed by LayerBio.
When was the press release announcing the trial commencement issued?
The press release was issued on December 2, 2025.
What type of therapy is OcuRing™-K?
OcuRing™-K is described as a drop-less sustained-release ocular therapy.
What is PainReform Ltd.'s role in this development?
PainReform Ltd. has commenced the development for the OcuRing™-K Phase II trial.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2025-12-02 09:40:05
Filing Documents
- zk2534080.htm (6-K) — 10KB
- exhibit_99-1.htm (EX-99.1) — 15KB
- image00001.jpg (GRAPHIC) — 371KB
- 0001178913-25-003983.txt ( ) — 538KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: December 2, 2025 PAINREFORM LTD. By: /s/ Ehud Geller Ehud Geller Executive Chairman of the Board and Interim Chief Executive Officer